IL6 and COVID-19: Considering the role of IL-6 pathway in the pathogenesis of severe COVID-19 and the confirmed LVL ability to block the IL-6 signaling, as well as its safety and good tolerability, we conducted a phase III clinical study to evaluate the efficacy and safety of LVL in subjects with severe COVID-19 [9].